Monsenso A/S

Monsenso A/S

CCPH:MONSO
0.21
DKK
+0.01
(+6.60%)
34.14MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.79
2.09
2.44
0.65
0.29
0.23
0.31
0.17
0.13
- -
Basic EPS, GAAP
-0.94
-0.58
-0.06
-0.34
-0.34
-0.29
-0.18
-0.09
-0.11
- -
Free Cash Flow per Basic Share
- -
-1.26
-0.36
-0.13
-0.64
-0.31
-0.01
-0.14
-0.05
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.36
1.06
1.14
1.18
0.88
0.55
0.34
0.21
0.1
0.07
Tangible Book Value per Share
-1.08
-1.28
-0.91
0.51
0.25
-0.04
-0.1
0.04
-0.03
-0.01
Basic Weighted Avg Shares
4
4
4
14
24
27
31
67
67
81
Sales/Revenue/Turnover
6
8
9
9
7
6
10
11
9
- -
Operating Margin (%)
-63.69
-27.63
1.9
-64.81
-126.29
-141.9
-60.26
-58.05
-85.12
- -
Depreciation Expense
1
2
2
4
4
5
4
4
5
- -
Net Income, GAAP
-3
-2
- -
-5
-8
-8
-5
-6
-7
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-52.33
-27.82
-2.56
-52
-114.14
-126.41
-55.66
-53.75
-81.03
- -
Working Capital
2
- -
-3
8
6
-1
-3
3
- -
- -
LT Debt
4
4
3
- -
- -
- -
- -
- -
2
1
Total Equity
5
4
4
19
21
15
11
14
7
7
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-47.86
-5.69
-41.44
-40.67
-43.4
-41.81
-47.94
-68.28
- -

Capital Structure

DKK

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
2
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
67
96
Market Capitalization
22
10
34

Working Capital

DKK

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
4
4
3
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
2
3
2
Inventories
- -
- -
- -
Total Current Liabilities
4
4
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

DKK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-12.61%
-50.75%
Free Cash Flow
- -
891.3%
-61.21%
Net Income, GAAP
- -
13.96%
20.26%
Sales/Revenue/Turnover
- -
3.3%
-20.22%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
11
2025
- -
- -
9
2026
- -
- -
- -

Semi-annual Earnings Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.09
2025
- -
- -
-0.11
2026
- -
- -
- -

Semi-annual Dividends Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Thomas Lethenborg
Full Time Employees
10
Sector
Technology services
Industry
Internet software/Services
Address
Rosenørns Allé 31, 2. Frederiksberg ZE Denmark 1970
IPO Date
Jun 10, 2020
Business
Monsenso A/S develops and sells a digital health solution for remote patient monitoring, treatment support, and research in mental healthcare, focusing on conditions including depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, addiction, and substance abuse. The company offers a CE-marked Class 1 medical device platform comprising a patient app for self-assessments, questionnaires, sensor data collection from smartphones and wearables, medication reminders, visualizations, motivational feedback, psychoeducation, cognitive behavioral therapy modules, and secure messaging; a carer app providing self-assessments, psychoeducation, and learning tools; a clinical web portal enabling patient data visualization, dashboards, historical overviews, correlation analysis, medical record keeping, messaging, and shared decision-making; and data analytics tools for historical data aggregation, statistical analysis, pattern recognition, predictive mood forecasting, and risk assessment. Founded in 2013 and headquartered in Frederiksberg, Denmark, Monsenso A/S operates primarily in Europe, serving patients, clinicians, carers, healthcare systems, social care organizations, pharmaceutical companies, insurers, private providers, and researchers through scalable SaaS subscriptions. In 2024, the company achieved 16% revenue growth to DKK 11.2 million, with 66% growth in commercial subscription revenues, alongside successful advancements in innovation projects such as PhaseV patient inclusions, upcoming Personae and MentBest studies, and new platform features including self-sign-up, e-consenting, dark mode, wearable integrations, video capabilities, and gamification.